"Golden moments" for Gyrus as it bucks dollar trend
This article was originally published in Clinica
Executive Summary
In spite of the preponderance of US dollar-denominated sales in its revenues mix, UK-based minimally invasive surgery products company Gyrus saw its first-half 2004 sales rise by 14% (26% on a constant exchange rate basis) to £42.5m ($75.7m). Profit before tax and goodwill amortisation was also up strongly, by 23%, at £3.7m, providing leverage on the sales growth and prompting executive chairman Brian Steer to talk of "major achievements" and of the "strength of the business model".
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.